Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection

Saudi Journal of Gastroenterology

Volumn 17, Issue 4, 2011, Pages 245-251

  Ahmed, Ahlam M ^a   Hassan, Magda S ^a   Abd Elsayed, Alaa ^b   Hassan, Huwayda ^c   Hasanain, Ahmad F ^a   Helmy, Ahmed ^a  

^a Assiut University Faculty of Medicine   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c Assiut University   (Egypt)

Author keywords

Hepatic fibrosis; hepatic steatosis; insulin resistance; metabolic syndrome; viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CLINICAL ASSESSMENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NECROINFLAMMATION; NECROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING;

ADULT; AGE DISTRIBUTION; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COMORBIDITY; DEVELOPING COUNTRIES; EGYPT; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79960222747     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.82578     Document Type: Article

References (50)

1. Marcellin P. Hepatitis C: The clinical spectrum of the disease. J Hepatol 1999;31:9-16. (Pubitemid 30002685)
2. Hoofnagle JH. Hepatitis C: The clinical spectrum of the disease. Hepatol 1997;26:15S-20.
3. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91. (Pubitemid 30137669)
4. Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, et al. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. World J Gastroenterol 2009;15:462-6.
5. Fartoux L, Chazouillres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41:82-7. (Pubitemid 40066385)
6. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004;16:1087-93. (Pubitemid 39488777)
7. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002;67:436-42. (Pubitemid 35303870)
8. Mofrad PS, Sanyal AJ. Nonalcoholic fatty liver disease. Med Gen Med 2003;5:14.
9. Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, et al. Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection. Intervirology 2009;52:49-56.
10. Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, et al. Diabetes mellitus in chronic hepatitis B and C: Prevalence and potential association with the extent of liver fibrosis. J Viral Hepatitis 2006;13:303-10.
11. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7. (Pubitemid 46144367)
12. Rafiq N, Younossi ZM. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2008;2:207-15.
13. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Mal PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15. (Pubitemid 30418941)
14. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis. J Hepatol 2005;43:38-44. (Pubitemid 40805271)
15. Shiha G, Seif S, Zalata K. Hepatic steatosis in chronic hepatitis C virus infection genotype 4: Prevalence and clinical correlations. Liver Int 2006;26:80.
16. Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: Does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 2004;49:25-9. (Pubitemid 38183740)
17. Jrmay K, Karcsony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 2005;11:6422-8. (Pubitemid 43136876)
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106: 3143-421.
19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
20. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74. (Pubitemid 29420675)
21. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host-and disease-specific factors affecting steatosis in chronic hepatitis. J Hepatol 1998;29:198-206. (Pubitemid 28352804)
22. Asselah T, Ripault MP, Marcellin P. What does chronic hepatitis C steatosis mean? Gastroenterol Clin Biol 2003;27:1073-5. (Pubitemid 38120637)
23. Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study. BMC Gastroenterol 2005;5:14.
24. Guidi M, Muratori P, Granito A, Muratori L, Pappas G, Lenzi M, et al. Hepatic steatosis in chronic hepatitis C: Impact on response to anti-viral treatment with peg-interferon and ribavirin. Alimen Pharmacol Therapeut 2005;22:943-9. (Pubitemid 41634875)
25. Friedenberg F, Pungpapong S, Zaeri N, Braitman LE. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab 2003;5:150-5. (Pubitemid 36519347)
26. Adinolfi LE, Utili R, Ruggiero G. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 1999;30:1530-1.
27. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41-6. (Pubitemid 40038898)
28. Poynter ME, Daynes RA. Peroxysome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-41. (Pubitemid 28557672)
29. Hzode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71. (Pubitemid 40911312)
30. Boccato S, Pistis R, Noventa F, Guido M, Benvegn L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006;13:297-302.
31. Baroni GS, Pastorelli A, Manzin A, Benedetti A, Marucci L, Solforosi L, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999;19:212-19. (Pubitemid 29261588)
32. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
33. Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003;38:307-14. (Pubitemid 36286543)
34. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-43. (Pubitemid 37363450)
35. Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, Tiniakos DG, Manesis EK, Archimandritis AJ. Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol 2009;44:752-9.
36. Hzode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003;52:126-9. (Pubitemid 36020778)
37. Camma C, Bruno S, Marco VD, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006;43:64-71. (Pubitemid 43738959)
38. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Chronic hepatitis C virus infection and insulin resistance: How do they interact, and what is the effect on hepatic fibrosis? Gastroenterology 2003;125:1695-704. (Pubitemid 37500434)
39. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-508. (Pubitemid 39435150)
40. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009;81:1032-9.
41. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003;38:1384-92. (Pubitemid 37466964)
42. Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: A way out for the virus? World J Gastroenterol 2009;15:5014-9.
43. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: Clinical and pathogenic data. Liver Int 2009;29:26-37.
44. Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: Impact on disease progression and treatment response. Liver Int 2009;29:3-12.
45. Zechini B, Pasquazzi C, Aceti A. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: The role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 2004;16:891-6. (Pubitemid 39179659)
46. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000;95:1545-50. (Pubitemid 30396318)
47. Al-Ashgar H, Helmy A, Khan MQ, Al-Kahtani K, Al-Quaiz M, Rezeig M, et al. Predictors of sustained viral response to a 48-week course of peginterferon a-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009;29:4-14.
48. Codes L, Asselah T, Cazals-Hatem D, Tubach F, Vidaud D, Paran R, et al. Liver fibrosis in women with chronic hepatitis C: Evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2007;56:390-5. (Pubitemid 46579771)
49. Serfaty L, Poujol-Robert A, Carbonell N, Chazouillres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002;97:1807-12. (Pubitemid 34761411)
50. Vadan R, Gheorghe L, Becheanu G, Iacob R, Iacob S, Gheorghe C. Predictive factors for the severity of liver fibrosis in patients with chronic hepatitis C and moderate alcohol consumption. Rom J Gastroenterol 2003;12:183-7. (Pubitemid 37152601)